Earch and has acted as a consultant for Bristol-MyersClinical Pharmacology: Advances and Applications 2013:submit your manuscript | www.dovepressDovepressWang et alDovepress 17. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib one hundred mg when everyday preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol. 2008;26(19): 3204212. 18. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves speedy and sturdy cytogenetic responses and higher transformation-free survival prices in chronic phase chronic myeloid leukemia individuals with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(two):23240. 19. Dasatinib (Sprycel) [webpage around the Internet]. Silver Spring, MD: US Meals and Drug Administration; 2010 [updated October 29, 2010]. Offered from: http://www.fda.gov/AboutFDA/CentersOffices/Offi ceofMedicalProductsandTobacco/CDER/ucm231538.htm. Accessed November eight, 2012. 20. Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Significance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol. 2008;48(11):1254269. 21. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011. 22. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once day-to-day minimizes the occurrence of pleural effusion in individuals with chronic myeloid leukemia in chronic phase and efficacy is unaffected in sufferers who create pleural effusion. Cancer. 2010;116(2):37786. 23. Litzow MR. Imatinib resistance: obstacles and possibilities. Arch Pathol Lab Med. 2006;130(5):66979. 24. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of every day imatinib mesylate 400 mg versus 800 mg in individuals with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase utilizing molecular finish points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3): 42430. 25. Saglio G, Kim DW, Issaragrisil S, et al; ENESTnd Investigators.Perfluorohexyloctane Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.AK-1 N Engl J Med.PMID:23892746 2010;362(24):2251259. 26. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of ideas and management suggestions of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041051. 27. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14(6):48593. 28. Marin D, Bazeos A, Mahon FX, et al. Adherence is the vital element for reaching molecular responses in individuals with chronic myeloid leukemia who accomplish total cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381388. 29. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence will be the primary purpose for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14): 3733736. 30. Kantarjian H, Sawyers C, Hochhaus A, et al; for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):64552. 31. Rosti G, Iacobucci I, Bassi S, et al. Impact of age around the outcome of patients with chronic myeloid leukemia in late chronic phas.
